Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03574779 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer
A Phase 2 study, sponsored by Tesaro.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT03574779: Completed Phase 2 study, sponsored by Tesaro.
NCT03574779 is a Phase 2 study that has completed, run by Tesaro. The registered enrollment target is 77 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03574779, a Phase 2 study, has completed, sponsored by Tesaro.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single arm) includes participants with recurrent ovarian cancer. Cohort B will not be initiated. Cohort C (randomized-2 arms) includes participants with newly diagnosed ovarian cancer.
Primary Outcome
Number of Participants enrolled across cohorts are presented.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL Bevacizumab
- DRUG Niraparib
- BIOLOGICAL TSR-042
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 2 |
What the finished NCT03574779 record still lists
NCT03574779 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT03574779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03574779 about?
NCT03574779 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer". This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single arm) includes participants with recurrent ovari...
What is the current status of trial NCT03574779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2018-11-15. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT03574779?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Bevacizumab (BIOLOGICAL), Niraparib (DRUG), TSR-042 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03574779?
This trial is sponsored by Tesaro, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03574779's enrollment target sits among peer trials
77 891st of 2000 higher than 1,108 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI